Archive for December, 2009

Noise Hurts Men’s Hearing More, Study Shows

Wednesday, December 23rd, 2009

New research suggests that men — especially married white men — are much more likely to develop noise-induced hearing loss than women. But there’s some good news: Another study finds that older men who take high doses of folate can decrease their risk of hearing loss by 20 percent.

The figures regarding hearing loss in men and women come from a study of hearing-test data from 5,290 people aged 20 to 69. An estimated 13 percent of them will suffer from noise-induced hearing loss, which researchers think affects about 24 million Americans.

The condition, caused by exposure to loud noise, is preventable.

Among the subjects, men were two-and-a-half times more likely than women to develop this type of hearing loss. Married, non-Hispanic white men had the highest risk, the study authors pointed out.

In another study, researchers found that increased doses of antioxidant vitamins don’t improve a man’s chances of avoiding hearing loss. But folate — a type of vitamin B — reduced the risk by 20 percent in men older than 60.

The findings came from a study of 3,559 men with hearing loss. Higher doses of antioxidant vitamins, such as vitamins C, E and beta carotene, had no effect, the researchers said.

Foods with high levels of folate include leafy vegetables such as spinach, lettuce and asparagus; dried or fresh beans; peas; liver products; and fortified cereal products.

The researchers pointed out that their study is the largest to look into links between diet and hearing loss.

Routine Testing Would Improve Herceptin Use in Breast Cancer

Tuesday, December 1st, 2009

New research suggests that the anti-breast cancer drug trastuzumab, also known as Herceptin, isn’t reaching its full potential. Many patients aren’t receiving tests that determine whether it’s appropriate or are taking it when they don’t need to.

Under current guidelines, women with breast cancer in its early stages should receive tests to see if Herceptin might be appropriate for them.

In the new study, researchers analyzed medical data to see if testing has become routine. Their findings will appear in the Nov. 15 issue of the journal Cancer.

As many as two-thirds of patients who were eligible for the testing didn’t appear to have had it. And about 20 percent of those who did take the drug appeared to have not taken the test to see if it could work for them in the first place, the researchers found.

In another complication, the research suggests that about one in five tests is inaccurate.

Filling the gaps in care “may help optimize limited health-care resources and improve care for women with breast cancer,” said study co-author Dr. Elena Elkin, a researcher at Memorial Sloan-Kettering Cancer Center in New York, in a news release from the journal’s publisher.

Doctors are increasingly trying to fine-tune treatments so they specifically target the disease in a particular patient, the researchers noted.

Routine Testing Would Improve Herceptin Use in Breast Cancer

Tuesday, December 1st, 2009

New research suggests that the anti-breast cancer drug trastuzumab, also known as Herceptin, isn’t reaching its full potential. Many patients aren’t receiving tests that determine whether it’s appropriate or are taking it when they don’t need to.

Under current guidelines, women with breast cancer in its early stages should receive tests to see if Herceptin might be appropriate for them.

In the new study, researchers analyzed medical data to see if testing has become routine. Their findings will appear in the Nov. 15 issue of the journal Cancer.

As many as two-thirds of patients who were eligible for the testing didn’t appear to have had it. And about 20 percent of those who did take the drug appeared to have not taken the test to see if it could work for them in the first place, the researchers found.

In another complication, the research suggests that about one in five tests is inaccurate.

Filling the gaps in care “may help optimize limited health-care resources and improve care for women with breast cancer,” said study co-author Dr. Elena Elkin, a researcher at Memorial Sloan-Kettering Cancer Center in New York, in a news release from the journal’s publisher.

Doctors are increasingly trying to fine-tune treatments so they specifically target the disease in a particular patient, the researchers noted.